Products estradiol, 10 mcg
estradiol, 10 mcg Phase 3 Completed 📈 Rising Menopause, Postmenopausal Vaginal Atrophy
Jan 1, 2007 → Nov 1, 2008
About estradiol, 10 mcg estradiol, 10 mcg is a phase 3 stage product being developed by Novo Nordisk for Menopause. The current trial status is completed. This product is registered under clinical trial identifier NCT00431132. Target conditions include Menopause, Postmenopausal Vaginal Atrophy.
Clinical Trials (2) NCT ID Phase Status Start Completion Indication NCT00431132 Phase 3 Completed Jan 1, 2007 Nov 1, 2008 Menopause NCT00108849 Phase 3 Completed Mar 1, 2005 May 1, 2007 Menopause
Product Company Stage Hype Score atomoxetine + placebo Eli Lilly Pre-clinical Fezolinetant + Placebo Astellas Pharma Phase 2 Cetrorelix Shionogi Pre-clinical Teriparatide (PTH 1-34) Eli Lilly Phase 2/3 Eszopiclone + Placebo Sumitomo Pharma Pre-clinical Comparator: placebo + Comparator: Estrace Merck Phase 1 esmirtazapine + Placebo Merck Phase 3 Marketed low dose hormone replacement therapy Novo Nordisk Pre-clinical 0.5 mg estradiol / 0.1 mg norethisterone acetate (NETA) Novo Nordisk Pre-clinical 1.0 mg estradiol / 0.5 mg norethisterone acetate (NETA) Novo Nordisk Approved estradiol, 10 mcg + estradiol, 25 mcg + placebo Novo Nordisk Phase 3 0.5 mg estradiol / 0.1 mg norethisterone acetate (NETA) + 0.5 mg estradiol / 0.25 mg norethisterone acetate (NETA) + 1.0 mg estradiol / 0.5 mg norethisterone acetate (NETA) Novo Nordisk Phase 1 estradiol, 25 mcg Novo Nordisk Pre-clinical estradiol, 10 mcg + estradiol, 25 mcg Novo Nordisk Phase 1 estradiol, 10 mcg Novo Nordisk Phase 3 2 mg estradiol / 1 mg norethisterone acetate (NETA) Novo Nordisk Phase 1 estradiol, 25 mcg Novo Nordisk Phase 3 estradiol, 25 mcg Novo Nordisk Phase 3 0.5 mg estradiol / 0.1 mg norethisterone acetate (NETA) + 0.5 mg estradiol / 0.25 mg norethisterone acetate (NETA) + placebo Novo Nordisk Phase 3 estradiol, 25 mcg + estradiol, 25 mcg Novo Nordisk Phase 1
Other Products from Novo Nordisk